|
CCDC122 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.39850000655673E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.33840000047381E-07 |
| Normal-vs-Stage2 |
1.84746999999374E-05 |
| Normal-vs-Stage3 |
1.8063999995821E-07 |
| Normal-vs-Stage4 |
3.06729999954847E-07 |
| Stage1-vs-Stage2 |
2.746400E-01 |
| Stage1-vs-Stage3 |
1.037810E-01 |
| Stage1-vs-Stage4 |
6.570200E-02 |
| Stage2-vs-Stage3 |
9.076600E-01 |
| Stage2-vs-Stage4 |
7.123600E-01 |
| Stage3-vs-Stage4 |
7.675200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.2619999468817E-09 |
| Normal-vs-AfricanAmerican |
5.223000E-04 |
| Normal-vs-Asian |
1.681380E-03 |
| Caucasian-vs-AfricanAmerican |
7.529600E-01 |
| Caucasian-vs-Asian |
1.437820E-01 |
| AfricanAmerican-vs-Asian |
2.150000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.3151000024605E-08 |
| Normal-vs-Female |
5.29220000045072E-08 |
| Male-vs-Female |
5.516800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.92289999995299E-06 |
| Normal-vs-Age(41-60Yrs) |
2.11299999719472E-08 |
| Normal-vs-Age(61-80Yrs) |
1.93219999999883E-07 |
| Normal-vs-Age(81-100Yrs) |
3.240100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.684420E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.142400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.592000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.547200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.162800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.737400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.029500E-02 |
| Classical-VS-Follicular |
8.717400E-01 |
| Classical-VS-Other |
4.583200E-01 |
| Classical-VS-Normal |
1.93320000008157E-07 |
| Tall-VS-Follicular |
1.903720E-02 |
| Tall-VS-Other |
6.177400E-01 |
| Tall-VS-Normal |
8.65370000102672E-08 |
| Follicular-VS-Other |
4.943400E-01 |
| Follicular-VS-Normal |
1.781570E-04 |
| Other-VS-Normal |
1.628300E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.31749999973974E-07 |
| Normal-vs-N1 |
3.612300000011E-06 |
| N0-vs-N1 |
6.521000E-01 |
|
|
